Immunotherapy and the Sequence Relative to Survival Outcomes in SCLC: Analysis of the National Cancer Database
This real-world analysis suggests that immunotherapy was associated with longer survival in ES-SCLC, CRT + IO is associated with improved OS, with a more obvious survival benefit when immunotherapy is initiated within 4-7 days after CRT. These findings hint at the potential importance of immunotherapy initiation sequence and warrant further prospective validation.
Authors
- Y. Liu
- Mengsi Cai (ORCID: https://orcid.org/0009-0008-8711-7135)
- Lan Huang (ORCID: https://orcid.org/0000-0001-6556-4067)
- Wenyao Yu (ORCID: https://orcid.org/0009-0001-8970-3997)
- Youwen He
- Y. Zhuang
- Sisi Zheng
- Dan Yao
Institutions
- Nebraska Medical Center (US)
- Duke University (US)
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- University of California San Diego (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-09
- DOI
- https://doi.org/10.3390/cancers18040567
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00